Encapsulation of drugs into lipid-based liquid crystalline (LC) phases offers a broadly applicable approach for the in vivo stabilization and sustained release delivery of peptides and proteins as well as small molecule drug substances. This is exemplifi ed by the FluidCrystal® 1 Injection depot, an adaptive drug delivery system, combining ease of manufacturing, handling, and injection, with long acting release. The system exploits specifi c liquid mixtures of naturally occurring polar lipids and small amounts of solvents, which upon contact with minute quantities of aqueous tissue fl uids self-assemble into reversed LC phases. The resulting encapsulation of dissolved or dispersed active pharmaceutical ingredients provides a release duration from a small volume injection, which is tunable from days to months.
Lipid Self-AssemblyLipids typically consist of a polar group chemically linked to one, two, or three hydrocarbon chains. As molecular entities, they are often classifi ed into polar and nonpolar lipids [ 1 ] . Nonpolar-lipids, e.g., triacylglycerols (triglycerides), interact only very weakly with water and do not form liquid crystal phases. Polar lipids, on the other hand, are amphiphilic in nature and interact more strongly with water and self-assemble to form a wide range of aqueous phases. These include solid phases characterized by the localization of hydrocarbon chains into weakly interacting layers, with the polar heads forming end-group planes via stronger interactions. On heating, the hydrocarbon chains are the fi rst to enter into the disordered liquid